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HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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Objectives: Estimate the direct cost of hepatitis C in Mexico, from the perspective 
of the health care system for the government employees, and simulate the economic 
impact of new antivirals. MethOds: We reviewed one hundred clinical records of 
patients diagnosed with chronic hepatitis C, to know the pattern of resources use at 
two hospitals of the health care system for the government employees, taking into 
account the disease stages based on the Child-Pugh. The inclusion criterion was 
patients with chronic HVC unresponsive to treatment or without the double viral 
therapy. Unit prices and costs of medical inputs were obtained from official sources. 
Demographic and clinical variables were also recorded in order to do compari-
sons. Statistical analysis of data was made with the SPSS. Simulation of economic 
impact of treatment with antivirals was done based on natural history of disease 
over a ten years horizon. Results: Annual mean costs of disease progression and 
complications were higher for Child-Pugh C (US$8,739) than B (US$6,319) and A 
(US$2,430). The estimated cost of one patient in Child-Pugh A stage not responding 
to peginterferon and ribavirin resulted in US$62,506 taking into account that this 
patient progress until Child-Pugh C. If the not responding patient could be treated 
with peginterferon, ribavirin and boceprevir the cost would be US$43,633, while a 
naive patient would cost US$34,302. cOnclusiOns: Hepatitis C imposes a high 
economic burden to the health care system for the government employees. The 
access of this population of patients to new antivirals would result in savings for 
the institution as well as increasing health benefits for patients.
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Objectives: To assess the potential trade-offs between aggressive screening (“test-
ing”) of the human immunodeficiency virus (HIV), early initiation of treatment 
(“test-and-treat”) with antiretroviral therapy (ART), and pre-exposure prophy-
laxis (PrEP) among men who have sex with men (MSM) in Los Angeles County 
(LAC). MethOds: A compartmental mathematical model is developed to simulate 
HIV incidence among 15-65 year old MSMs of LAC over a twenty-year period, and 
estimate the cost and effectiveness of various HIV interventions using a societal 
perspective and a lifetime horizon. Annual LAC MSM population data (2000-2010) 
are estimated from the LAC HIV Surveillance Reports and the RAND California 
Population and Demographics database. The model input parameter values are 
derived from the published clinical literature and the Federal Supply and IMS Fee 
Schedules. For each intervention, we estimate the number of new HIV infections 
averted, the discounted costs and quality-adjusted life years (QALYs), and the incre-
mental cost per infection averted and cost-effectiveness ratios. Bootstrapping and 
probabilistic sensitivity analyses are conducted to assess the robustness of the 
estimates. Results: Our preliminary results show that relative to the status quo 
policy, and at the current US willingness to pay threshold of $100,000/QALY saved, 
both the PrEP, “testing” and “test-and-treat” strategies are cost-effective ($86,194; 
$44,746 and $94,520 per QALY saved, respectively). These results are imputable to 
the preventive and survival benefits of PrEP, knowledge of infection status, and early 
treatment. The relative effectiveness of PrEP is sensitive to PrEP and ART adherence 
and coverage rates. All cost-effectiveness profiles improve with ART price reductions 
following patent expiration. cOnclusiOns: PrEP, “testing” and “test-and-treat” 
offer cost-effective alternatives to the status-quo policy. The success of the PrEP 
and “test-and-treat” strategies remains particularly contingent on the uptake rate 
and adherence to treatment. The lack of evidence on adherence behaviors towards 
PrEP thus warrants further studies that mimic real-world adherence patterns.
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Objectives: Determine the cost-effectiveness of small intestinal submucosa extra-
cellular matrix (SISEM) relative to standard of care (SC) on wound closure for the 
treatment of mixed arterial/venous (A/V) or venous (VLUs) leg ulcers. MethOds: 
A 2-stage Markov model was used to predict the expected costs and outcomes of 
wound closure for SISEM and SC. Outcome data used in the analysis were taken 
from an 8-week randomized clinical trial that directly compared SISEM and SC. 
Patients were followed for 6 months to assess wound closure. Forty-eight patients 
completed the study; 25 for SISEM and 23 for SC. SC was defined as a standard moist 
wound dressing. Transition probabilities for the Markov states were estimated from 
the clinical trial. The economic outcome of interest was direct cost per ulcer-free 
week. Resource utilization was based on the treatment regimen used in the clini-
cal trial. Costs were derived from standard cost references. The payer’s perspective 
was taken. Results: SISEM-treated wounds healed, on average, after 5.4 weeks of 
treatment, compared to 8.3 weeks for SC wounds (p= 0.02). Furthermore, complete 
wound closure was significantly higher for patients treated with SISEM (p< 0.05), 
with 20 wounds closed in the SISEM group (80%) and 15 wounds closed in the SC 
PIN39
receNt treNDs IN costs, leNGtH of stay, aND mortalIty assocIateD 
WItH INfaNt PertussIs HosPItalIzatIoNs IN tHe uNIteD states
Davis K.L., Kurosky S.
RTI Health Solutions, Research Triangle Park, NC, USA
Objectives: Pertussis incidence has resurged in the US after a nadir in the 1970s 
and is now one of the most prevalent vaccine-preventable infections. Infants are 
at greatest risk for severe pertussis-related morbidity and mortality (~50% of infant 
cases require hospitalization) and account for the majority of cases. We sought to 
quantify the cost and mortality burden of infant pertussis cases severe enough 
to prompt hospitalization. MethOds: Data on pertussis-related hospitalizations 
(ICD-9-CM discharge codes 033.0, 033.8, 033.9, 484.3) from the 2000-2010 Nationwide 
Inpatient Sample (NIS) were retrospectively analyzed. Charges were converted to 
costs using a 0.5 cost-to-charge ratio. Weighted, nationally representative estimates 
of costs per admission (in 2013 US dollars), length of stay (LOS), and case fatality 
rates (CFRs) were descriptively assessed for each year. Results: Total numbers 
of infant pertussis hospitalizations in the US followed a cyclic pattern, starting at 
2,282 in 2000 and peaking at 5,343 in 2005, then declining to 1,614 in 2007 before 
another peak of 3,220 in 2010. Mean [SD] LOS for these hospitalizations fluctuated 
minimally year-to-year, but an overall (albeit modest) increase was observed: from 
3.3 [7.3] days in 2000 to 3.9 [9.5] days in 2010. Mean [SD] cost per admission increased 
at a greater rate than LOS, from $12,377 [$23,985] in 2000 to $16,339 [$37,224] in 2010. 
Both LOS and costs were more than double those observed for non-pertussis hospi-
talizations. CFRs were relatively stable during the period, fluctuating between ~1.5% 
and 3%, although a peak of 4.4% occurred in 2005 coinciding with the incidence 
peak. cOnclusiOns: Infant pertussis hospitalizations typically exceed 3 days and 
are associated with high costs compared with hospitalizations for other causes. 
Observed CFRs were consistent with the ~2% fatality rate previously derived from 
CDC surveillance. These data may help inform economic and cost-effectiveness 
evaluations of future pertussis vaccination programs.
PIN40
cost of erytHroPoIetIN use IN tHe early access ProGram of 
telaPrevIr for tHe treatmeNt of metavIr f3-f4 PatIeNts WItH 
GeNotyPe 1 Hcv IN brazIl
Morais A.D.1, Magno L.A.1, Nogueira C.V.2
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2UFRJ, Brazil
Objectives: To estimate the direct medical costs associated with the use of eryth-
ropoietin (EPO) in the treatment of anemia in patients with advanced fibrosis and 
cirrhosis (METAVIR F3-F4) receiving telaprevir in association with peg-interferon and 
ribavirin (TVR+PR) in the early access program in Brazil. MethOds: Anemia events 
and EPO use during TVR therapy were gathered from published results of 97 patients 
in the early access program (EAP) of TVR in Brazil. Anemia treatment was assumed 
to be one vial of erythropoietin (EPO) 40.000U per week. Medication unit costs were 
gathered from a public (SUS) and private payer perspective in Brazil. Sensitivity 
analysis was carried out for anemia treatment duration and patients with EPO 
use. A sub-analysis was performed to estimate the cost of anemia treatment with 
boceprevir (BOC+PR) based on data from the phase 3 clinical trials. Results: The 
cost of EPO during TVR+PR treatment in the EAP /anemic patient was R$ 10.190,04 
from a private payer perspective compared to R$ 3.545,06 from a SUS perspective. 
The average cost of EPO was R$ 4.727,34 /patient from a private payer perspec-
tive and R$ 1.644,87 /patient from the SUS perspective. Considering the sensitivity 
analysis, the total cost of EPO treatment ranged between R$ 382.126,50-R$ 601.212,36 
from a private payer perspective compared to R$ 132.960,00-R$ 209.190,40 from a 
SUS perspective for all patients. Considering EPO use for BOC+PRr, the average ane-
mia treatment cost was R$ 7.851,34 /patient from a private payer perspective and 
R$ 2.731,86 /patient from a SUS perspective. cOnclusiOns: In a real life setting, 
TVR+PR was associated with EPO use although few patients discontinued treatment. 
Compared to EPO use in clinical trials, TVR+PR was associated with less EPO costs 
than BOC+PR in a real life setting such as the Brazilian EAP.
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Objectives: The objective was to estimate, in a real-life setting, the health care 
resource utilization, more specifically resource utilization for management of the 
most common adverse events (AE) associated with current treatment of hepatitis 
C virus (HCV) infection. MethOds: A retrospective study of the Quebec provin-
cial drug reimbursement program (RAMQ) was conducted using a random sample 
of patients who filed at least one script at the pharmacy for an HCV medication 
(pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) from 
2007 to 2013. Data on medical (excluding nurse visits) and pharmaceutical services 
were extracted from the RAMQ database. We report health care resources used 
during HCV treatment including outpatient physician’s visits and procedures, emer-
gency visits, hospitalization days and costs associated with adverse events, which 
included medical services and medications. Results: A total of 962 patients who 
used at least one HCV medication were included in the study (mean age: 47.9 years 
(SD= 10.7), 61.5% males). The proportion of patients who used Peg-Riba only, Peg-
Riba + boceprevir and Peg-Riba + telaprevir was 90.5%, 8.2% and 3.4% and treatment 
duration was 31.5 weeks, 30.4 weeks and 21.6 weeks respectively. During HCV treat-
ment, the average number of health care resources used per patient was 13.2 physi-
cian’s visits and procedures, 0.8 hospitalization day and 0.8 emergency visit. While 
receiving HCV treatment, 20.8% of patients required erythropoietin, 33.3% received 
rash treatments and 48.8% were treated for depression. Estimated costs associated 
with management of these three AE were CDN$11,199, CDN$85 and CDN$282 per 
patient respectively, for a total of CDN$2,399,258 for this cohort. cOnclusiOns: 
